

# ANCO FAX News

Association of Northern California Oncologists  
Post Office Box 151109, San Rafael, California 94915-1109  
Voice: (415) 472-3960 • FAX: (415) 472-3961  
[execdir@anco-online.org](mailto:execdir@anco-online.org) • [www.anco-online.org](http://www.anco-online.org)

Vol. 16, No. 4

February 24<sup>th</sup>, 2017

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association and membership news*. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at [www.anco-online.org/pubs.html](http://www.anco-online.org/pubs.html).

#### In this issue:

- ASCO & NCCN to collaborate on practical clinical guidelines
- CMS telehealth fact sheet published
- *17<sup>th</sup> Multidisciplinary Management of Cancers: A Case-based Approach*—REGISTRATION ENDS FEB 28

**The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts) Members.** The next regular *ANCO FAX News* will be published on March 10<sup>th</sup>. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960; FAX: (415) 472-3961; [execdir@anco-online.org](mailto:execdir@anco-online.org).

**The *ANCO FAX News* has information for every member of your practice or organization. Pass it along!**

- Physician Members
- Nurses & Office Managers
- Office Staff
- Colleagues & Representatives

The *Association of Northern California Oncologists* (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge. The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

## ADVOCACY

[Editor's Note: ANCO is a member of the Association of Community Cancer Centers (ACCC) and a state/regional affiliate of the American Society of Clinical Oncology (ASCO). ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) Council on Legislation, House of Delegates, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

### **ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues**

ASCO and NCCN have announced that they plan to jointly collaborate to publish practical clinical guidelines on the management of side effects caused by immunotherapy. Working together, each organization will use its standard methodology to develop and publish clinical practice guidelines under the lead of a multidisciplinary expert panel. At time of completion, two separate guidelines will be published: ASCO systemic review-based guideline and NCCN algorithmic guidelines. These guidelines are expected later this year.

CMS has released its updated telehealth factsheet reflecting changes made to Medicare telehealth reimbursement in CY2017, including the addition of new CPT codes for end-stage renal disease (ESRD) related services for dialysis and advance care planning codes to the list of codes eligible for reimbursement when delivered through telehealth. It also includes an explanation of the new place of service (POS) code specifically designated to indicate telehealth was used. For more information, go to [www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/MLN-Publications-Items/CMS1243327.html](http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/MLN-Publications-Items/CMS1243327.html).

CMS's Medicare Quality Payment Program website is at [qpp.cms.gov](http://qpp.cms.gov). The Program will implement the Merit-Based Incentive Payment System (MIPS) and the Advanced Alternative Payment Model (APM) incentive payment provisions of MACRA. For more information, go to:

- CMS's executive summary at [qpp.cms.gov/docs/QPP\\_Executive\\_Summary\\_of\\_Final\\_Rule.pdf](http://qpp.cms.gov/docs/QPP_Executive_Summary_of_Final_Rule.pdf)

- CMS's fact sheet at [qpp.cms.gov/docs/Quality\\_Payment\\_Program\\_Overview\\_Fact\\_Sheet.pdf](http://qpp.cms.gov/docs/Quality_Payment_Program_Overview_Fact_Sheet.pdf).
- CMS's tool for physicians to review and select the MACRA quality measures that best fit their practice at [qpp.cms.gov/measures/quality](http://qpp.cms.gov/measures/quality)
- ASCO's analysis of and comments on the final rule at [www.asco.org/advocacy-policy/asco-in-action/asco-releases-analysis-macra-final-rule-and-quality-payment-program](http://www.asco.org/advocacy-policy/asco-in-action/asco-releases-analysis-macra-final-rule-and-quality-payment-program) and [www.asco.org/sites/new-www.asco.org/files/content-files/ASCO-2016-MACRA-Comments-Final.pdf](http://www.asco.org/sites/new-www.asco.org/files/content-files/ASCO-2016-MACRA-Comments-Final.pdf).
- ASCO's fact sheets to help oncology practices successfully participate in the QPP at [www.asco.org/macra](http://www.asco.org/macra)
- ACCC's MACRA presentation at [www.anco-online.org/ACCCMACRAPresentation.pdf](http://www.anco-online.org/ACCCMACRAPresentation.pdf).
- ASH's summary of the final rule at [www.hematology.org/Advocacy/Policy-News/2016/6755.aspx](http://www.hematology.org/Advocacy/Policy-News/2016/6755.aspx), comments on the final rule at [www.hematology.org/Advocacy/Testimony.aspx](http://www.hematology.org/Advocacy/Testimony.aspx), and MACRA 101 for Hematologists at [ashondemand.org/Areas/Redesign/Content/MACRA\\_101\\_11-15-16.pdf](http://ashondemand.org/Areas/Redesign/Content/MACRA_101_11-15-16.pdf).
- Bobbi Buell's analysis of the MACRA final rule at [www.anco-online.org/BBMacraFinalRule.pdf](http://www.anco-online.org/BBMacraFinalRule.pdf)
- The California Medical Association's (CMA) MACRA Resource Center at [www.cmanet.org/macra](http://www.cmanet.org/macra)

Download the presentations from ASCO's webinar entitled *MACRA Rules are Final: Time to Implement* at [www.asco.org/practice-guidelines/practice-management-issues/medicare-program/macra](http://www.asco.org/practice-guidelines/practice-management-issues/medicare-program/macra).

CMS has extended the deadline from February 28<sup>th</sup> to March 13<sup>th</sup> for the 2016 Quality Reporting Document Architecture (QRDA) data submission for the EHR reporting mechanism. This affects all individual eligible professionals and PQRS practices. Eligible professionals who do not satisfactorily report 2016 quality measure data to meet the PQRS requirements will be subject to a downward PQRS payment adjustment on all Medicare Part B Physician Fee Schedule services rendered in 2018. For more information, please go to [www.cms.gov/](http://www.cms.gov/)

medicare/quality-initiatives-patient-assessment-instruments/pqrs/analysisandpayment.html.

In related news, **ACCC is creating tools and resources for cancer programs as part of its *Optimizing Electronic Health Records (EHRs) education initiative.*** To assist ACCC in shaping these resources, please share your EHR pain points and success via their survey at [www.surveymonkey.com/r/2017ACCCEHR](http://www.surveymonkey.com/r/2017ACCCEHR).

**The deadline to submit reconsideration applications for the 2017 EHR Incentive Program payment adjustment—based on the 2015 reporting period—is February 28<sup>th</sup>.**

Applications will not be accepted after the deadline. The reconsideration application is at [www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/Downloads/PaymentAdj\\_ReconsiderationFormEP.pdf](http://www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/Downloads/PaymentAdj_ReconsiderationFormEP.pdf); the instructions are at [www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/Downloads/PaymentAdj\\_ReconsiderationInstructEP.pdf](http://www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/Downloads/PaymentAdj_ReconsiderationInstructEP.pdf).

### **CMA, MOASC, and State Legislative & Regulatory Issues**

The *California Oncology Political Action Committee* (or CalCancerPAC), formed by ANCO and MOASC, supports candidates sensitive to the needs of hematologists/oncologists and people living with cancer in California. ANCO membership dues include a contribution to CalCancerPAC.

*CMA Practice Resources (CPR)* is a monthly e-mail bulletin from CMA's *Center for Economic Services* that is full of tips and tools to help physicians and their office staff improve practice efficiency and viability. Subscribing to CPR is free and open to anyone, but CMA membership is necessary to access the resources, toolkits, forms, and tools that are located on the members-only CMA website. Please visit [www.cmanet.org/cpr](http://www.cmanet.org/cpr) to subscribe.

### **Noridian/JEMAC, DHCS/MediCal, & Private Payers**

*Noridian Administrative Services* is the *Jurisdiction E (JE) Medicare Administrative Contractor (MAC)*. Jurisdiction E includes California. Regularly review postings at the *Noridian/JEMAC* website at [med.noridianmedicare.com/web/jeb](http://med.noridianmedicare.com/web/jeb). Recent

updates include:

- MLN Connects Provider eNews *Announcements*—Clinical Laboratories: Easier to Report Lab Data *Claims, Pricers, and Codes*—January 2017 OPPS Pricer File *Publications*—Medicare Home Health Benefit Booklet-Revised
- Positron Emission Tomography Scans Coverage-R8
- MolDX-CDD: Oncotype DX Breast Cancer for DCIS (Genomic Health) Final LCD-Effective March 27, 2017
- Revalidation Enrollment on Demand Tutorials
- QMB Indicator in the Medicare Fee-For-Service Claims Processing System CR9911
- NCCI PTP Edits, Version 23.1, Effective April 1, 2017-Quarterly Update CR9970
- HCPCS Codes Subject to and Excluded from CLIA Edits CR9946
- Medicare Outpatient Observation Notice (MOON) Instructions-Revised CR9935

*Noridian/JEMAC's* Electronic Data Interchange Support Services (EDISS) invites you to subscribe to its e-mail distribution list to receive current information at [www.edissweb.com/cgp/news/index.html](http://www.edissweb.com/cgp/news/index.html).

### **Forthcoming Noridian/JEMAC meetings/workshops include:**

- Radiation Oncology (February 28)
- Duplicate Claims (March 1)
- Screening Services (March 9)
- Noridian Medicare Portal Functionality for Part B Providers (March 23)

Visit [med.noridianmedicare.com/web/jeb/education/training-events](http://med.noridianmedicare.com/web/jeb/education/training-events) for more information and to register.

*Anthem Blue Cross* is implementing important changes to its national drug list (formulary) effective April 1<sup>st</sup>. Review these changes at [file.anthem.com.s3-website-us-east-1.amazonaws.com/64774CAEENABC.pdf](http://file.anthem.com.s3-website-us-east-1.amazonaws.com/64774CAEENABC.pdf).

The *Anthem Network Update* (February 2017) is now available online at [www11.anthem.com/ca/provider/f5/s3/t3/pw\\_g296540.pdf](http://www11.anthem.com/ca/provider/f5/s3/t3/pw_g296540.pdf) and features articles entitled *Clinical guideline/medical policy*

update; New specialty pharmacy program for utilization review of drug dosage and frequency; Contracted provider claim escalation process; and, Clinical practice and preventive healthy guidelines available online.

## EDUCATION

[Editor's Note: ANCO organizes clinical and professional education meetings throughout the year and throughout Northern California.]

### **17<sup>th</sup> Multidisciplinary Management of Cancers: A Case-based Approach REGISTRATION ENDS February 28<sup>th</sup>**

The 17<sup>th</sup> Multidisciplinary Management of Cancers: A Case-based Approach returns to the Silverado Resort and Spa in Napa on March 17-19<sup>th</sup>. The meeting is sponsored by the Association of Northern California Oncologists, Stanford Cancer Institute, UC Davis Comprehensive Cancer Center, and the UCSF Helen Diller Family Comprehensive Cancer Center. Go to [www.multicancers.org](http://www.multicancers.org) to register.

### **Additional Education Meetings**

March 2<sup>nd</sup>

ASCO Oncology Practice Conference

ASCO

Orlando

([opc.asco.org](http://opc.asco.org))

March 3<sup>rd</sup>-4<sup>th</sup>

ASCO Quality Care Symposium: Quality Matters

ASCO

Orlando

([quality.asco.org](http://quality.asco.org))

March 6<sup>th</sup>

Managing Eye and Vision Changes Related to Cancer Treatments

CancerCare Connect Education Workshop

([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

March 7<sup>th</sup>

Update on Small Cell Lung Cancer Treatments:

Part I of Living with Small Cell Lung Cancer

CancerCare Connect Education Workshop

([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

March 8<sup>th</sup>

Palliative Care, Value-Based Payment and the Patient Experience

ACCC Webinar

(<https://attendeegotowebinar.com/register/4558826277352706819>)

March 8<sup>th</sup>

Understanding the Role of Immunotherapy in Testing Cancer—Part I of Immunotherapy: A Promising New Approach to Treating Cancer  
CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

March 10<sup>th</sup>

Living with Cancer Throughout the Cancer Journey  
CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

March 11<sup>th</sup>

Regional Summit: GAIN—EnGaging an Interdisciplinary Team for NSCLC Diagnosis, Personalized Assessment & Treatment  
NCCN

San Francisco

([www.chestnet.org/Education/Advanced-Clinical-Training/CHEST-GAIN-NSCLC](http://www.chestnet.org/Education/Advanced-Clinical-Training/CHEST-GAIN-NSCLC))

March 13<sup>th</sup>

9<sup>th</sup> Annual Palliative Care Summit

Coalition for Compassionate Care of California  
Sacramento

([cccs Summit.org](http://cccs Summit.org))

March 13<sup>th</sup>

An Ongoing Journey to Advance Molecular Testing in Lung Cancer

ACCC & AMP

(<https://attendeegotowebinar.com/register/2573310585943935235>)

March 14<sup>th</sup>

Diagnostics in Small Cell Lung Cancer: How Diagnostics Help Inform Treatment Decisions—Part II of Living with Small Cell Lung Cancer  
CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

March 15<sup>th</sup>

Managing the Side Effects of Immunotherapy—Part II of Immunotherapy: A Promising New Approach to Treating Cancer

CancerCare Connect Education Workshop

([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

March 15<sup>th</sup>

Management of Immune-related Adverse Events in Patients with Non-Small Cell Lung Cancer (NSCLC)

ACCC Institute for Clinical Immuno-Oncology

(<https://attendeegotowebinar.com/register/7236769310437359617>)

March 16<sup>th</sup>

The Role of Genetics Professionals in a Community Cancer Program

ACCC & AMP  
(<https://attendee.gotowebinar.com/register/2573310585943935235>)

March 16-18<sup>th</sup>  
*Multidisciplinary Thoracic Cancers Symposium: Bringing Precision Medicine to Thoracic Cancer Care*  
American Society Clinical Oncology  
San Francisco  
([www.thoracicsymposium.org/index.aspx](http://www.thoracicsymposium.org/index.aspx))

March 23<sup>rd</sup>  
*Update on Glioblastoma*  
CancerCare Connect Education Workshop  
([www.cancercares.org/connect\\_workshops](http://www.cancercares.org/connect_workshops))

March 24<sup>th</sup>  
*Clinical Genetics vs Tumor Genomic Profiling: Relevance in Cancer Care*  
ACCC & AMP  
(<https://attendee.gotowebinar.com/register/2573310585943935235>)

March 28<sup>th</sup>  
*Progress in the Treatment of Follicular Lymphoma*  
CancerCare Connect Education Workshop  
([www.cancercares.org/connect\\_workshops](http://www.cancercares.org/connect_workshops))

March 29<sup>th</sup>-31<sup>st</sup>  
*Cancerscape: Business & Policy, Value & Quality—ACCC 43<sup>rd</sup> Annual Meeting*  
Association of Community Cancer Centers  
Washington, DC  
([www.accc-cancer.org/meetings/AM2017.asp](http://www.accc-cancer.org/meetings/AM2017.asp))

April 3<sup>rd</sup>  
*Advances in the Treatment of Colorectal Cancer*  
CancerCare Connect Education Workshop  
([www.cancercares.org/connect\\_workshops](http://www.cancercares.org/connect_workshops))

April 5<sup>th</sup>  
*Progress in the Treatment of Oral and Head and Neck Cancer*  
CancerCare Connect Education Workshop  
([www.cancercares.org/connect\\_workshops](http://www.cancercares.org/connect_workshops))

April 6<sup>th</sup>  
*Update on Chronic Lymphocytic Leukemia (CLL)*  
CancerCare Connect Education Workshop  
([www.cancercares.org/connect\\_workshops](http://www.cancercares.org/connect_workshops))

April 20<sup>th</sup>-22<sup>nd</sup>  
*Cancer Metastasis through the Lymphovascular System: Biology & Treatment—7<sup>th</sup> International Symposium*  
Sentinel Node Oncology Foundation  
San Francisco  
([www.cancermetastasis.org](http://www.cancermetastasis.org))

Please contact the ANCO office for more information about these meetings.

## ASSOCIATION & MEMBERSHIP NEWS, RESOURCES, & BENEFITS

[Editor's Note: All ANCO members are also eligible for several tangible benefits.]

### Board of Directors

The ANCO *Board of Directors* meets by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and professional education, and ways to better serve the membership. *Board* teleconferences/meetings are open to individual physician members. The **next regularly scheduled ANCO Board of Directors meeting is scheduled for March 21<sup>st</sup>**. Please call José Luis González, *ANCO Executive Director*, at (415) 472-3960 if you wish to participate in a future teleconference/meeting.

### Individual Member News

A current *Directory of Members* is available online at [www.anco-online.org/pubs.html](http://www.anco-online.org/pubs.html) as a .pdf document. We urge all ANCO members to download their own edition of *The ANCO Directory of Members*. Please verify your *Directory* entry and contact the ANCO office at [execdir@anco-online.org](mailto:execdir@anco-online.org) with any corrections, additions, and/or deletions.

### Group Member News

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and benefits and a mutual set of interests. The ANCO *Board* believes that the *Association* and *The Permanente Medical Group* (TPMG) will each receive value from Group Membership.

ANCO initiated a **Multi Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks *Diablo Valley Oncology & Hematology Medical Group*, *EPIC Care*, *Marin Cancer Care*, *Pacific Cancer Care*, *Palo Alto Medical Foundation*, and *Valley Medical Oncology Consultants* for their multi site group memberships.

### Institutional Member News

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or*

Oncology of accredited, degree granting teaching universities or research institutions are eligible for institutional membership. ANCO thanks the following Institutional Members for their support:

- *Stanford Cancer Center*
- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

**Stanford's Neuroendocrine Tumors in 2017: New Diagnostics and Therapies takes place on March 4<sup>th</sup> at Stanford.** For more information and to register, go to [cme.stanford.edu/nets](http://cme.stanford.edu/nets).

### Corporate Member News

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

*AbbVie • Agendia • Alexion Pharmaceuticals  
AMGEN • ARIAD Pharmaceuticals  
Astellas Oncology • AstraZeneca  
Bayer Healthcare Pharmaceuticals  
bioTheranostics  
Boehringer Ingelheim Pharmaceuticals  
Bristol-Myers Squibb Oncology  
Cardinal Health Specialty Solutions  
Celgene • Clovis Oncology • Daiichi Sankyo  
Dendreon • Eisai • EMD Serono • Exelixis  
Foundation Medicine  
Genoptix Medical Laboratory  
GenPath Oncology • Genentech BioOncology  
Genomic Health • Gilead Sciences  
Guardant Health • Helsinn Oncology  
Heron Therapeutics • Incyte  
Infinity Pharmaceuticals  
Ipsen Biopharmaceuticals  
Janssen Oncology • Jazz Pharmaceuticals  
Lilly Oncology • Merrimack Pharmaceuticals  
Medivation • Merck  
nanoString • Novartis Oncology  
Oncology Supply/ION • Pfizer Oncology  
Pharmacyclics • Prometheus Laboratories, Inc.  
Sandoz Biopharmaceuticals • Sanofi Genzyme  
Seattle Genetics • Taiho Oncology  
Takeda Oncology • Tesaro • TEVA Oncology*

We especially wish to thank and welcome *Agendia*, *bioTheranostics*, and *EMD Serono* as new Corporate Members for 2017. Please visit [www.anco-online.org/assistance.html](http://www.anco-online.org/assistance.html) for **Corporate Member drug**

**reimbursement and patient assistance program information.** ANCO encourages all member practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

*Celgene* informs ANCO that the *United States Food and Drug Administration* has approved Revlimid as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.

*Janssen Biotech* is hosting an educational program entitled *Darzalex-based Triplet Therapy for Multiple Myeloma Patients at First Relapse* with Amy Marsala, M.P., *UC San Francisco*, on March 17<sup>th</sup> at *Morimoto*, 610 Main Street, Napa. RSVP at [www.medforcereg.net/SOMP108529](http://www.medforcereg.net/SOMP108529).

### Clinical Trial News

**Stanford Cancer Center brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:**

- A Phase I Study of BLU-285 in Patients with Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies (HEMMPD0027; NCT02561988]. Principal Investigator: Jason Gotlib, MD; Contact: Isabel Reyes, (650) 725-4047, [ilreyes@stanford.edu](mailto:ilreyes@stanford.edu)
- Longterm Follow-up of Subjects with bb2121 (HEMML0026; NCT02786511]. Principal Investigator: Michaela Liedke, MD; Contact: Reneth D. Tien, (650) 723-0646, [rtien@stanford.edu](mailto:rtien@stanford.edu)
- A Phase I Study of bb2121 in BCMA-Expressing Multiple Myeloma (HEMML0025; NCT02658929]. Principal Investigator: Michaela Liedke, MD; Contact: Reneth D. Tien, (650) 723-0646, [rtien@stanford.edu](mailto:rtien@stanford.edu)
- Intratumoral Injection of SD-101, an Immunostimulatory CpG, in combination with Ibrutinib and Local Radiation in Relapsed or Refractory Low-Grade Follicular Lymphoma (LYMNL0135; NCT02927964]. Principal Investigator: Ronald Levy, MD; Contact: Ami Akada, (650) 725-4968, [amio@stanford.edu](mailto:amio@stanford.edu)
- A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared with Best Supportive Care Following Adjuvant Cisplatin Based Chemotherapy in PD-L1-Selected Patients with Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (LUN0076; GO295276; NCT02486718]. Principal Investigator: Heather Wakelee, MD; Contact: Liza Zhou, (650) 736-4112, [yaya@stanford.edu](mailto:yaya@stanford.edu)
- A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects with Light Chain

(AL) Amyloidosis who have Persistent Cardiac Dysfunction (HEM0045; NCT02632786). Principal Investigator: Michaela Liedke, MD; Contact: Uzma Ahmed, (650) 723-0670, uzma.ahmed@stanford.edu

- A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (HEMCLL0021; NCT02717611). Principal Investigator: Steven Coutre, MD; Contact: Linda Griffin, (650) 736-8210, lcgriff1@stanford.edu

- A Phase Ib, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL; HEMALL0012; NCT02404220). Principal Investigator: Michaela Liedke, MD; Contact: Uzma Ahmed, (650) 723-0670, uzma.ahmed@stanford.edu

- A Phase Dose Escalation Study of Ibrutinib with Idarubicin/Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia (HEMAML0036; NCT02635074). Principal Investigator: Steven Coutre, MD; Contact: Jack Taw, (650) 723-2781, jtaw@stanford.edu

- PALLAS: PALbociclib CoLLaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer (ECOG-ACRIN-PRE0109; NCT02513394). Principal Investigator: Melinda Telli, MD; Contact: Annabel Castaneda, (650) 498-7977, annabelc@stanford.edu

- Phase I/II Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer (BRS0063; NCT02657889). Principal Investigator: Melinda Telli, MD; Contact: Janet Pan, (650) 723-0628, janetpan@stanford.edu

- A Phase I Study of BPM31510 Plus Vitamin K in Subjects with Glioblastoma that has Recurred on a Bevacizumab Containing Regimen (BRN0035; NCT03020602). Principal Investigator: Seema Nagpal, MD; Contact: Sophie Bertrand, (650) 723-4467, sophieb@stanford.edu

- A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination with Corticosteroids versus Placebo in Combination with Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD; BMT311; NCT02959944). Principal Investigator: David Miklos, MD; Contact: Janet McDowell, (650) 725-1647, janetm2@stanford.edu

- Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination with Nivolumab in Adult Subjects with Advanced Refractory Solid Tumor

Malignancies [VAR0143; NCT02904226]. Principal Investigator: Shivaani Kummar, MD; Contact: Ferial Buchholz, (650) 721-4090, ferielbu@stanford.edu

- A Phase I/Ib, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers [VAR0141; NCT02655822]. Principal Investigator: Shivaani Kummar, MD; Contact: Stephanie Ezrati, (650) 723-6498, ezratis@stanford.edu

Further information is available at [cancer.stanford.edu/trials/](http://cancer.stanford.edu/trials/).

### **Publications, Resources, Services, & Surveys**

**CancerLinQ and the *American Society for Radiation Oncology* (ASTRO) are partnering to bring radiation oncology expertise to CancerLinQ and improve the care of cancer patients nationwide.** ASTRO will provide guidance for the development of the CancerLinQ platform to ensure that the system captures more relevant patient data to drive actionable decision-making in cancer care, as well as to advance public policy and population health issues. ASTRO also will use insights from CancerLinQ Discovery to improve the care of patients receiving radiation therapy. For more information, visit [www.asco.org/advocacy-policy/asco-in-action/cancerlinq-partners-premier-radiation-oncology-society](http://www.asco.org/advocacy-policy/asco-in-action/cancerlinq-partners-premier-radiation-oncology-society).

**ASCO's *Clinical Affairs Department* is dedicated to providing services, education, and resources to support oncology practices.** It offers hands-on assistance in areas such as practice management, quality care assessment and improvement, and efficiency and business intelligence to meet the needs and demands of the current oncology landscape. Resources on the business of oncology, practice management (staffing, technology), practice transformation, and market analysis are available from the *Department*. For more information, visit [www.asco.org/asco-in-action/asco's-clinical-affairs-department-opens-new-survey-practice-operations](http://www.asco.org/asco-in-action/asco's-clinical-affairs-department-opens-new-survey-practice-operations).

**ASCO's 2017 *Quality Training Program*, a six-month course in data-driven quality improvement,** will now take place in two locations—Dallas and Portland. The session dates for Portland are April 20<sup>th</sup>-21<sup>st</sup>, June 28-29<sup>th</sup>, and October 18<sup>th</sup>. To learn more about and apply to participate in the Program, visit

[www.asco.org/training-education/professional-development/quality-training-program](http://www.asco.org/training-education/professional-development/quality-training-program).

The *American Society for Clinical Pathology (ASCP)*, the *College of Pathologists (CAP)*, the *Association for Molecular Pathology (AMP)*, and the *American Society of Clinical Oncology (ASCO)* have collaborated to develop the *Molecular Biomarkers for the Evaluation of Colorectal Cancer guideline*. The guideline addresses testing a wide range of molecular biomarkers in patients with early and advanced colorectal cancer and will help to establish standard molecular biomarker testing, guide targeted therapy decisions, and advance personalized care for patients with colorectal cancer. Read the guideline at [ascopubs.org/doi/abs/10.1200/JCO.2016.71.9807](http://ascopubs.org/doi/abs/10.1200/JCO.2016.71.9807).

**ASCO's PracticeNET is a collaborative network in which practices share and receive insights to enhance their business operations and quality of care.** PracticeNET is the first initiative of ASCO's *Clinical Affairs Department*. This new initiative uses existing data from your practice management system to offer customizable reports that measure practice-wide and individual performance against a national database of other PracticeNET participants. Go to [www.asco.org/PracticeNET](http://www.asco.org/PracticeNET) for more information.

A new ASCO Special Article in the *Journal of Oncology Practice* highlights a joint *National Institute for Occupational Safety and Health (NIOSH)* and ASCO workshop on the safe handling of hazardous drugs. Read the article at [ascopubs.org/doi/full/10.1200/JOP.2016.017384](http://ascopubs.org/doi/full/10.1200/JOP.2016.017384).

The February 2017 issue of ASCO's *Journal of Oncology Practice (JOP)* is available online and features articles entitled *Establishing a Core Set of Performance Measures to Improve Value in Cancer Care: ASCO Consensus Conference Recommendation Report*; *Capturing High-Value Cancer Care in the Wild*; *Integration of Palliative Care Into Standard Oncology Care: ASCO Clinical Practice Guideline Update Summary*; *Radiation Therapy for Glioblastoma: ASCO Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline*; and, *Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline Summary*. Visit [jop.ascopubs.org](http://jop.ascopubs.org) for more information.

A new collaboration between ASCO and the *American Board of Internal Medicine (ABIM)* enables participants of ASCO's *Quality Oncology*

*Practice Initiative (QOPI)* to receive *Maintenance of Certification (MOC) Practice Assessment points* from ABIM. For more information on ABIM MOC, eligibility and requirements, please visit [university.asco.org/practice-assessment-activities](http://university.asco.org/practice-assessment-activities).

ASCO and *Innovative Oncology Business Solutions (IOBS)* have announced a new collaboration, ASCO COME HOME—an oncology medical home program designed to transition community oncology practices from volume-based to value-based care by structuring reimbursement around the full range of services needed by patients with cancer. ASCO COME HOME will also prepare oncology practices for full implementation of the Quality Payment Program under MACRA and will be available across the country starting on January 1<sup>st</sup>, 2017. ASCO is now recruiting practices for the fee-based 2017 ASCO COME HOME program. For more information, please contact Elaine Towle ([elaine.towle@asco.org](mailto:elaine.towle@asco.org)). Learn more about ASCO's physician payment reform efforts at [www.asco.org/advocacy-policy/policies-positions-guidance/coverage-reimbursement/physician-payment-reform](http://www.asco.org/advocacy-policy/policies-positions-guidance/coverage-reimbursement/physician-payment-reform).

**In 2017, practices will also be able to use the QOPI platform to meet the MIPS reporting requirement of one measure through manual reporting.** While one measure is the minimum requirement to avoid the 2019 penalty, ASCO encourages all practices to report on at least four measure to become fully acquainted with the system and ensure that the CMS requirements are met.

**See what you missed at this year's ASH Annual Meeting by visiting ASH on Demand to access more than 100 hours of recorded sessions.** Go to [ashondemand.org/Meetings/Annual-Meetings](http://ashondemand.org/Meetings/Annual-Meetings) for more information.

ACCC's online *Oncology Drug Database* provides quick access to information on oncology drug coding, billing, and reimbursement at [www.accc-cancer.org/drugdatabase/](http://www.accc-cancer.org/drugdatabase/).

ACCC's enhanced set of *Financial Advocacy Network* resources are at [www.accc-cancer.org/resources/FinancialAdvocacy-Overview.asp](http://www.accc-cancer.org/resources/FinancialAdvocacy-Overview.asp). This "one-stop" destination for comprehensive financial advocacy information includes online training materials, practical financial advocacy tools, peer-to-peer networking, and more.

ACCC's 2017 *Patient Assistance and*



**Reimbursement Guide is an essential tool for cancer program staff to use in helping patients with issues related to the cost of treatment and in meeting reimbursement challenges.** The *Guide* features a list of pharmaceutical and non-pharmaceutical patient assistance programs (PAPs), including directions on how to apply and links to enrollment forms. Visit [www.accc-cancer.org/publications/pdf/Patient-Assistance-Guide-2017.pdf](http://www.accc-cancer.org/publications/pdf/Patient-Assistance-Guide-2017.pdf) to access this resource. In addition, ACCC has developed a tool for accessing patient assistance and reimbursement programs for use on a desktop, table, or mobile device. The *Financial Advocacy Network* (FAN) app is available at [acc-fan-app.org](http://acc-fan-app.org). **ASH also has a webpage (at [www.hematology.org/Clinicians/Drugs/Programs/](http://www.hematology.org/Clinicians/Drugs/Programs/)) that provides a consolidated list of resources for hematologists and patients trying to access high cost hematologic drugs.** And, at NCCN's Reimbursement Resource Room ([www.nccn.org/reimbursement\\_resource\\_room/default.asp](http://www.nccn.org/reimbursement_resource_room/default.asp)) you can select a cancer diagnosis or supportive care indication and learn about reimbursement help and services available to you. Finally, *assistPoint* is your website for complimentary one-stop cancer Patient Assistance. You can search by generic, brand name, manufacturer, or diagnosis for the enrollment forms you need; get enrollment form PDFs for cancer drugs; get NDC numbers for all of those drugs; find the HCPCS J-code for each drug; get coding and billing guidelines for many drugs; and, learn more about the drugs you give. Go to [www.assistpoint.com](http://www.assistpoint.com) to learn more.

**The Community Oncology Alliance (COA) has launched the Advance Practice Provider Network (CAPP Network) to support advanced practice providers (NPs, PAs, etc.).** To join the CAPP Network visit [www.communityoncology.org/capp](http://www.communityoncology.org/capp).

**The Community Oncology Alliance Administrator's Network has a great set of resources.** Tools are available for E&M services, HR forms, and dozens of other office forms. The resources are free, but join the *Network* for more information. The resources are available online at [can.communityoncology.org/site/forms.htm](http://can.communityoncology.org/site/forms.htm).

**NCCN has published and/or updated their Clinical Practice Guidelines in Oncology and/or Drugs & Biologics Compendium** for antiemesis (V1.2017); B-cell lymphomas (V2.2017); bladder cancer (V2.2017); chronic lymphocytic leukemia/small lymphocytic lymphoma (V2.2017); hairy cell leukemia (V2.2017); kidney

cancer (V2.2017); neuroendocrine tumors (V1.2017); non-small cell lung cancer (V4.2017); occult primary (cancer of unknown primary, chemotherapy order templates); prevention and treatment of cancer-related infections (V2.2017); prostate cancer (V2.2017); systemic light chain amyloidosis; T-cell lymphomas (V2.2017); and, Waldenstrom's macroglobulinemia (V1.2017). Go to [www.nccn.org](http://www.nccn.org) for more information. NCCN is pleased to offer pocket-sized versions of the NCCN *Clinical Practice Guidelines in Oncology* for a number of their guidelines at [www.nccn.org/redirects/nicelines.asp?Type=general](http://www.nccn.org/redirects/nicelines.asp?Type=general).

*Oplinc* is a national organization that was founded with the purpose of developing a collaborative environment within the oncology community. The *Oplinc Best Practices Review Newsletter*, sponsored by *Lilly Oncology* and written by Risë Cleland, provides an in-depth look at the issues and challenges facing oncology practices. Download the latest edition (focusing on Medicare's Proposed *Physician Fee Schedule* for 2017) at [oplinc.com/newsletter/BestPracticesReviewJan-Feb2017.html](http://oplinc.com/newsletter/BestPracticesReviewJan-Feb2017.html).

### **Individual Membership Dues for 2017**

**Second notices of membership renewal for 2017 were mailed to all members in early February.** If you have not yet done so, then please return your 2017 membership dues to ANCO now to ensure your inclusion in *The ANCO Directory of Members*. Be sure to provide ANCO with your e-mail address and the name(s) and e-mail address(es) of office and/or nurse manager contact(s). Those not renewing their membership by June 30<sup>th</sup> will be deleted from the *Directory of Members*, and will no longer be eligible for any ANCO benefits. Contact the ANCO office if you do not receive or misplaced your membership dues renewal notice.

ANCO seeks new members. **All members of a practice should join ANCO.** And, ANCO seeks to enroll radiation oncologists as members, so please send us contact information for the radiation oncologists within your practice and/or to whom you refer patients.

**Remember, a larger ANCO is a stronger ANCO!**